Transgene Initiates A Phase I Trial Of Its Therapeutic Vaccine Candidate TG4040 For Patients Chronically Infected With The Hepatitis C Virus

Thu, 15 Feb 2007 02:00 PM EST

... Transgene S.A. (Eurolist Paris: FR0005175080) announces today that the first patients have been enrolled in a Phase I trial of its therapeutic vaccine candidate TG4040 (MVA-HCV) for patients chronically infected with the Hepatitis C Virus (HCV). The trial is part of a development programme supported by Lyonbiopole, one of France's six world-class competitiveness clusters. [click link for full article] ...